Gefitinib

證據等級: L5

預測適應症: 10 個

Gefitinib: From Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Gefitinib is a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) known clinically for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for Fibromatosis, Gingival, but this direction is currently supported by 0 clinical trials and 0 publications — it is a model-score-only prediction with no mechanistic or empirical backing.

Quick Overview

Item	Content
Original Indication	Not recorded in the local regulatory registry (0 licenses on file). Based on known pharmacology, gefitinib is an EGFR-TKI indicated for EGFR mutation-positive non-small cell lung cancer (NSCLC).
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.89%
Evidence Level	L5
Norway Market Status	Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the local registry (data gap DG002). Based on known pharmacological information from the evidence pack itself, gefitinib is a first-generation EGFR tyrosine kinase inhibitor that blocks EGFR autophosphorylation and downstream RAS/MEK/ERK signalling, and it is the standard-of-care mechanism for EGFR-mutant NSCLC.

Gingival fibromatosis, however, is a benign connective-tissue overgrowth disorder with no established link to EGFR-driven oncogenic signalling. The evidence pack's own mechanistic assessment for this candidate states explicitly that there is no known mechanistic connection between gefitinib's EGFR-TKI activity and gingival fibromatosis, and no clinical trial or literature evidence exists to support the association. This candidate therefore appears to be a pure knowledge-graph score artifact (TxGNN rank 1590) rather than a biologically grounded repurposing hypothesis.

It is worth noting that several lower-ranked predictions in this evidence pack (e.g., lung hilum carcinoma, lung germ cell tumor, pulmonary sulcus neoplasm) are anatomically and mechanistically closer to gefitinib's established NSCLC indication, though even these lack indication-specific trial or literature confirmation. See Conclusion for further discussion.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Gefitinib currently holds no marketing authorization in Norway (0 licenses on file; market status: 未上市 / Not Marketed).

Cytotoxicity

Gefitinib is an antineoplastic agent (original indication class: NSCLC; drug class confirmed across the evidence pack's own mechanistic rationales as an EGFR tyrosine kinase inhibitor).

Item	Content
Cytotoxicity Classification	Targeted therapy (EGFR tyrosine kinase inhibitor; not a conventional cytotoxic chemotherapy agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The featured prediction (gingival fibromatosis, TxGNN score 99.89%) has no clinical trial or literature support and no plausible mechanistic link — it is a model-score-only (L5) association. This is compounded by a Blocking data gap (DG001: TFDA/local label warnings and contraindications unavailable), which prevents even an initial safety screen (S1), and by the drug having zero marketing authorizations locally.

To proceed, the following is needed:

Resolve DG001 (obtain and parse the official package insert for warnings/contraindications) before any S1 safety evaluation can occur.
Resolve DG002 (confirm MOA via DrugBank API) to properly document mechanistic rationale.
If gingival fibromatosis remains the target, generate a specific mechanistic hypothesis and seek preclinical/case-level evidence — none currently exists.
Consider re-scoping evaluation toward the more anatomically plausible candidates in this pack (rank 5, lung hilum carcinoma, which reached decision_stage S1 / "Research Question"), which — while still weakly supported — are mechanistically closer to gefitinib's established NSCLC activity.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.